Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of HG381 as Monotherapy in Patients With Advanced Solid Tumors
Latest Information Update: 05 Mar 2024
Price :
$35 *
At a glance
- Drugs HG 381 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors HitGen
- 28 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 28 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
- 20 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.